Risk Evaluation and Mitigation Strategy

Last Revised:
January 23, 2012
Published on:
Monday, January 23, 2012

This presentation slide set was delivered by representatives from the ACCME, the Food and Drug Administration, and AstraZeneca during the session entitled "Risk Evaluation and Mitigation Strategies:  Developing REMS (CE) in...

On July 9, the US Food and Drug Administration (FDA) released its Risk Evaluation and Mitigation Strategy or REMS for extended-release and long-acting (ER/LA) opioid analgesics.

The centerpiece of the ER/LA Opioid Analgesic...

Member Organization Meetings Address MOC, REMS

The ACCME participated in the following meetings during the past few months as part of its ongoing...

ACCME Data Shows Scope of CE on ER/LA Opioid REMS

The ACCME has released a ...

The American Nurses Credentialing Center (ANCC) hosted a Standards for Commercial Support Users Group meeting on February 21. The meeting followed up on discussions the participants held in August about the role of accreditors in...

Presentation about CE's role in ER/LA Opioid Analgesics REMS

The ...

Murray Kopelow, MD, ACCME Chief Executive, was interviewed for Reach MD Radio about CME as a strategic asset to public health initiatives, including the Food and Drug Administration’s Risk Evaluation and...

PARS Modifications Support REMS Data Collection and Auditing Process

...